MedTrace Logo

State Immunization Information Systems to Improve HPV Vaccination Rates

NCT02993965 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 77716

Last updated 2020-08-20

No results posted yet for this study

Summary

The overarching goal of this study is to evaluate the effectiveness, cost-effectiveness and sustainability of utilizing statewide Immunization Information Systems (IIS) to conduct centralized reminder/recall (R/R) to improve Human Papiloma Virus (HPV) vaccination rates among adolescents ages 11-17 (with a more focused look at the new two dose series for 11-14 year olds).

Conditions

  • Vaccine
  • Human Papiloma Virus Vaccine
  • HPV Vaccine
  • Immunization
  • Health Registry
  • Adolescent Health
  • Reproductive Health
  • Preventive Health Services

Interventions

OTHER

Vaccine Reminder/Recall

The investigators will be sending recall notices via phone call or postcard to 11-17 year olds or 11-14 year olds who are eligible but lacking HPV vaccine doses recorded in the Colorado Immunization Information System (CIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention) for bringing children 11-17 years old up to date on HPV vaccination. They will also be testing the effectiveness and cost effectiveness of using mail vs. phone call reminder notices (as compared to no intervention) for bringing 11-14 year olds up to date on HPV vaccination.

Sponsors & Collaborators

Principal Investigators

  • Allison Kempe, MD · University of Colorado, Denver

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
11 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-21
Primary Completion
2019-03-15
Completion
2020-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02993965 on ClinicalTrials.gov